Standard operating procedure: minnow takes the risk up to/including trials, toxicology, formulation etc, major company pays for the right to progress to market and sales. I'd imagine they will pay much more later on the development track ( less risk ) , rather than pay less at the early developmental stages (most risk).
Major pharmaceutical companies have their finger on every potential new/ongoing drug development ( & no they wouldn't be relying on HC threads for their market intelligence ).
Speculative M&A Transaction Analysis, page-729
-
- There are more pages in this discussion • 126 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.010(0.63%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.56 | $168.3K | 106.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 51 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |